Clario and XingImaging expand partnership to deliver PET imaging clinical trials in China
PR93968
BEIJING and PRINCETON, N.J., Jan. 11, 2022 /PRNewswire=KYODO JBN/ --
Clario, a technology company that delivers the leading endpoint technology
solutions for clinical trials, and XingImaging, a radiopharmaceutical
production and positron emission tomography (PET) acquisition company, have
expanded their partnership to deliver PET imaging clinical trials for testing
novel therapeutics in China.
Logo - https://mma.prnewswire.com/media/1677749/Clario_Logo.jpg
Clario, formerly ERT and Bioclinica, and XingImaging joined forces in 2018 to
support multi-center clinical trials requiring PET for eligibility and drug
efficacy evaluation. PET imaging has supported novel studies for Alzheimer's
disease (AD) and other neurodegenerative diseases. A dedicated team of
neuroscientists and project managers have led multiple trials in China to date.
The new expanded offering leverages the joint resources and neuroscience
experts of Clario and XingImaging to expedite the startup of clinical trials
and drug discovery in China, including amyloid, tau, and other targets.
"Broadening our scope of clinical trials to further support drug development in
neuroscience presents a unique opportunity for both patients and clinical
researchers," says Joyce Suhy, PhD, SVP Medical Imaging at Clario. "Our
continued partnership with XingImaging is advancing therapeutics in APAC."
"XingImaging is proud to be working with Clario in providing PET imaging
multi-center clinical trials," says Gilles Tamagnan, CEO XingImaging, LLC. "Our
partnership enables patients in China to participate in clinical trials testing
novel neurodegenerative disease therapeutics."
About Clario
Clario delivers the leading endpoint technology solutions for clinical trials.
Through experience gained from over 19,000 clinical trials delivered in support
of 870 regulatory approvals, Clario fuses scientific expertise and global scale
into the broadest endpoint technology platform to enable pharmaceutical,
biotech and medical device partners to transform lives. Through Trial
Anywhere™, Clario has mastered the ability to generate rich evidence across all
trial models: decentralized, hybrid and site-based clinical trials. With 30
facilities in nine countries across North America, Europe and Asia Pacific,
Clario's global team of science, technology and operational experts has been
delivering the richest clinical evidence for nearly 50 years.
About XingImaging LLC
XingImaging fills the distinctive clinical research role of a
radiopharmaceutical production and PET acquisition CRO in the People's Republic
of China. Established in January 2018 with that goal, XingImaging is a
recognized US based biomarker imaging company leading radiopharmaceutical
imaging trials in China. With firmly-rooted study teams on the ground in China
and the US, XingImaging works in collaboration with biotech and pharmaceutical
companies for the testing and advancement of therapeutics through brain imaging.
For more information, please visit Clario.com (
) and XingImaging.com or follow us on LinkedIn (
) and Twitter (
).
Clario Media Contact
Suzanne Harris
Senior Director, Corporate Brand and Marketing
suzanne.harris@clario.com
+1 484-274-7333
SOURCE Clario
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
